Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design
详细信息 查看全文
- 作者：James M. Chen ; Frances C. Nelson ; Jeremy I. Levin ; Dominick Mobilio ; Franklin J. Moy ; Ramaswamy Nilakantan ; Arie Zask ; and Robert Powers
- 刊名：Journal of the American Chemical Society
- 出版年：2000
- 出版时间：October 11, 2000
- 年：2000
- 卷：122
- 期：40
- 页码：9648 - 9654
- 全文大小：588K
- 年卷期：v.122,no.40(October 11, 2000)
- ISSN：1520-5126
文摘
The high-resolution NMR solution structure of the catalytic fragment of human collagenase-3 (MMP-13) was used as a starting point for structure-based design of selective inhibitors for MMP-13. The majorstructural difference observed between the MMP structures is the relative size and shape of the S1' pocketwhere this pocket is significantly longer for MMP-13, nearly reaching the surface of the protein. On the basisof the extended nature of the MMP-13 S1' pocket an inhibitor potent and selective for MMP-13 was designedfrom an initial high throughput screening (HTS) lead. CL-82198 was identified as a weak (10 
M) inhibitoragainst MMP-13 while demonstrating no activity against MMP-1, MMP-9, or the related enzyme TACE. Thedrug-like properties of CL-82198 made it an ideal candidate for optimization of enzyme potency and selectivity.On the basis of NMR binding studies, it was shown that inhibitor CL-82198 bound within the entire S1'pocket of MMP-13 which is the basis of its selectivity against MMP-1, MMP-9, and TACE. A strategy utilizingthis information was devised for designing new inhibitors that showed enhanced selectivity toward MMP-13.Our design strategy combined the critical selectivity features of CL-82198 with the known potency features ofa nonspecific MMP inhibitor (WAY-152177) to generate a potent and selective MMP-13 inhibitor (WAY-170523). WAY-170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivityagainst MMP-1, MMP-9, and TACE, respectively.
M) inhibitoragainst MMP-13 while demonstrating no activity against MMP-1, MMP-9, or the related enzyme TACE. Thedrug-like properties of CL-82198 made it an ideal candidate for optimization of enzyme potency and selectivity.On the basis of NMR binding studies, it was shown that inhibitor CL-82198 bound within the entire S1'pocket of MMP-13 which is the basis of its selectivity against MMP-1, MMP-9, and TACE. A strategy utilizingthis information was devised for designing new inhibitors that showed enhanced selectivity toward MMP-13.Our design strategy combined the critical selectivity features of CL-82198 with the known potency features ofa nonspecific MMP inhibitor (WAY-152177) to generate a potent and selective MMP-13 inhibitor (WAY-170523). WAY-170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivityagainst MMP-1, MMP-9, and TACE, respectively.